These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
463 related articles for article (PubMed ID: 29382774)
1. Lymphocytic response to tumour and deficient DNA mismatch repair identify subtypes of stage II/III colorectal cancer associated with patient outcomes. Williams DS; Mouradov D; Jorissen RN; Newman MR; Amini E; Nickless DK; Teague JA; Fang CG; Palmieri M; Parsons MJ; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Faragher I; Jones IT; Gibbs P; Sieber OM Gut; 2019 Mar; 68(3):465-474. PubMed ID: 29382774 [TBL] [Abstract][Full Text] [Related]
2. Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation. Williams DS; Mouradov D; Newman MR; Amini E; Nickless DK; Fang CG; Palmieri M; Sakthianandeswaren A; Li S; Ward RL; Hawkins NJ; Skinner I; Jones I; Gibbs P; Sieber OM Mod Pathol; 2020 Jul; 33(7):1420-1432. PubMed ID: 32047231 [TBL] [Abstract][Full Text] [Related]
3. Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis. Gil-Raga M; Jantus-Lewintre E; Gallach S; Giner-Bosch V; Frangi-Caregnato A; Safont-Aguilera MJ; Garde-Noguera J; Zorraquino-Pina E; García-Martínez M; Camps-Herrero C Clin Transl Oncol; 2018 Nov; 20(11):1422-1429. PubMed ID: 29802524 [TBL] [Abstract][Full Text] [Related]
4. Deficient DNA mismatch repair is associated with favorable prognosis in Thai patients with sporadic colorectal cancer. Korphaisarn K; Pongpaibul A; Limwongse C; Roothumnong E; Klaisuban W; Nimmannit A; Jinawath A; Akewanlop C World J Gastroenterol; 2015 Jan; 21(3):926-34. PubMed ID: 25624727 [TBL] [Abstract][Full Text] [Related]
5. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Sinicrope FA; Shi Q; Smyrk TC; Thibodeau SN; Dienstmann R; Guinney J; Bot BM; Tejpar S; Delorenzi M; Goldberg RM; Mahoney M; Sargent DJ; Alberts SR Gastroenterology; 2015 Jan; 148(1):88-99. PubMed ID: 25305506 [TBL] [Abstract][Full Text] [Related]
6. Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. Etienne-Grimaldi MC; Mahamat A; Chazal M; Laurent-Puig P; Olschwang S; Gaub MP; Formento JL; Formento P; Sudaka A; Boige V; Abderrahim-Ferkoune A; Benchimol D; André T; Houry S; Faucheron JL; Letoublon C; Gilly FN; Delpero JR; Lasser P; Pradere B; Pezet D; Penault-Llorca F; Milano G Br J Cancer; 2014 May; 110(11):2728-37. PubMed ID: 24800948 [TBL] [Abstract][Full Text] [Related]
7. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813 [TBL] [Abstract][Full Text] [Related]
8. Intertumoral Heterogeneity of CD3 Yoon HH; Shi Q; Heying EN; Muranyi A; Bredno J; Ough F; Djalilvand A; Clements J; Bowermaster R; Liu WW; Barnes M; Alberts SR; Shanmugam K; Sinicrope FA Clin Cancer Res; 2019 Jan; 25(1):125-133. PubMed ID: 30301825 [TBL] [Abstract][Full Text] [Related]
10. Tumor microenvironment classification based on T-cell infiltration and PD-L1 in patients with mismatch repair-proficient and -deficient colorectal cancer. Liu S; Kong P; Wang X; Yang L; Jiang C; He W; Quan Q; Huang J; Xie Q; Xia X; Zhang B; Xia L Oncol Lett; 2019 Feb; 17(2):2335-2343. PubMed ID: 30675299 [TBL] [Abstract][Full Text] [Related]
11. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair. Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788 [TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single-center retrospective study of 1,834 Chinese patients with Stage I-IV colorectal cancer. Guo TA; Wu YC; Tan C; Jin YT; Sheng WQ; Cai SJ; Liu FQ; Xu Y Int J Cancer; 2019 Sep; 145(6):1625-1634. PubMed ID: 31162857 [TBL] [Abstract][Full Text] [Related]
13. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. Sinicrope FA; Foster NR; Thibodeau SN; Marsoni S; Monges G; Labianca R; Kim GP; Yothers G; Allegra C; Moore MJ; Gallinger S; Sargent DJ J Natl Cancer Inst; 2011 Jun; 103(11):863-75. PubMed ID: 21597022 [TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive role of DNA mismatch repair status in stage II-III colorectal cancer: A systematic review and meta-analysis. Deng Z; Qin Y; Wang J; Wang G; Lang X; Jiang J; Xie K; Zhang W; Xu H; Shu Y; Zhang Y Clin Genet; 2020 Jan; 97(1):25-38. PubMed ID: 31432497 [TBL] [Abstract][Full Text] [Related]
15. Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. Zaanan A; Shi Q; Taieb J; Alberts SR; Meyers JP; Smyrk TC; Julie C; Zawadi A; Tabernero J; Mini E; Goldberg RM; Folprecht G; Van Laethem JL; Le Malicot K; Sargent DJ; Laurent-Puig P; Sinicrope FA JAMA Oncol; 2018 Mar; 4(3):379-383. PubMed ID: 28983557 [TBL] [Abstract][Full Text] [Related]
16. Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer. Chen X; Yang Z; Feng J; Duan T; Pan T; Yan L; Jin T; Xiang Y; Zhang M; Chen P; Wang W; Zhang R; Chen B; Zhao L; Xie T; Sui X Cancer Med; 2021 Jan; 10(1):317-324. PubMed ID: 33174323 [TBL] [Abstract][Full Text] [Related]
17. Different surgical outcome and follow-up status between dMMR and pMMR colorectal cancer patients who fulfilled with Amsterdam-II criteria. Sun CY; Chiang JM; Chen TC; Hung HY; You JF World J Surg Oncol; 2020 Aug; 18(1):195. PubMed ID: 32767993 [TBL] [Abstract][Full Text] [Related]
18. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Venderbosch S; Nagtegaal ID; Maughan TS; Smith CG; Cheadle JP; Fisher D; Kaplan R; Quirke P; Seymour MT; Richman SD; Meijer GA; Ylstra B; Heideman DA; de Haan AF; Punt CJ; Koopman M Clin Cancer Res; 2014 Oct; 20(20):5322-30. PubMed ID: 25139339 [TBL] [Abstract][Full Text] [Related]
19. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study. Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771 [TBL] [Abstract][Full Text] [Related]
20. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients. Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]